



New Ways of Making Vaccines

Plant-derived vaccine production technology

IT'S TIME TO FIND NEW WAYS OF MAKING VACCINES

Since the mid 1980's, we have been relying on the same technologies to produce vaccines: eggs, mammalian cells, insect cells, yeast and bacterial cells. The mRNA technologies developed during the recent COVID pandemic require high infrastructure costs from production to patient delivery, and these new approaches are not yet accessible for everyone.

The world needs new ways of making vaccines – new ways that allow us to respond to infections faster, cheaper and safer with minimal infrastructure required; we cannot solely rely on the existing ways of making vaccines anymore.

ASPIRE INNOVA'S TECHNOLOGY IS THE SOLUTION

Aspire Innova is developing a unique plant-derived vaccine production technology which is cost-effective, fast, animal and environmental friendly, scalable, safe, regulatory accepted. The technology which minimizes limitations of existing vaccine production technologies.

Aspire Innova is on a mission to make vaccines accessible for anyone from anywhere to achieve sustainable reduction and eradication of infectious diseases worldwide.

THERAPEUTIC PIPELINE: HERPES SIMPLEX VIRUS INFECTIONS


To date, herpes simplex virus infections remain incurable and challenging to prevent with millions of cases worldwide. Herpes infections are shown to be linked to a number of neurodegenerative diseases including Alzheimer's disease. Aspire Innova intends to develop therapeutic vaccine candidates using Aspire Innova's Technology to combat Herpes infections. Later on, we intend to progress our development to tackle other infectious diseases through licensing and co-development.

COMPETITIVE LANDSCAPE AND MARKET ANALYSIS

Aspire Innova enters a unique niche market having no direct competitors from either plant-derived or herpes simplex vaccines on the market to date. Market sizes in both fields are depicted below:

The global plant-derived therapeutic market (Transparency Market Research, n.d.)	The global herpes simplex virus treatment market (IMARC Group, n.d.)
2020: reached US\$1.10 Bn 2031: will reach US\$2.34 Bn CAGR of 7.38% from 2021 to 2031	2021: reached US\$2.32 Bn 2027: will reach US\$3.25 Bn CAGR of 5.50% from 2022 to 2027

ASPIRE INNOVA'S DEVELOPMENT PLAN



Funding requirements:

Seeking: 900.000 EUR
(to reach Milestone 4)

- FFG (500K EUR, applied)
- INITS (100K EUR, apply Dec '23)
- Private equity (300K, Jan'23)

Use of Proceeds:

- Laboratory rental /Equipment/reagents
- Hiring (2Sci.,2Technician)
- Office rental ('24)

Competitive Advantages:

- Sci.Technical know-how: Bench-bedside
- Management: Innovation and Business Management
- International and diverse background
- Investment-ready startup

Founding Team:

- Supawadee Payomnoi, B. Pharm, MBA('23) (Founder/CEO/ Sci. Innovation Strategist)
- Halyna Pankevych, PhD. (Sci. Innovation Development Lead)
- Crysthel Pamintuan, MBA (Chief Business Relations/ Development Officer)
- Dmitry Sokolov, CFA, MBA (Chief Financial Officer)
- Wanhui You, PhD. (Translational Sci. Lead)

